Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial.

104 (58%) ctDNA+ within 2 years after RC, 63% of those within 4 months.

Ann Oncol 2026;37(5):712-724.PubMed 41544704